Selecting an in vivo model for cancer-immunotherapy efficacy hinges on aligning immune competence, tumor antigen presentation, and tumor-microenvironment fidelity with the therapeutic mechanism under study. Alfa Cytology provides syngeneic, humanized, cell-line–derived xenograft, and orthotopic mouse models that support rigorous preclinical evaluation across diverse tumor types.

Diverse of Preclinical Oncology Models

Capturing the complexity of tumor biology demands a spectrum of preclinical oncology models that reflect diverse immune contexts, genetic drivers, and microenvironmental cues. Alfa Cytology equips researchers with diverse in-vivo platforms—spanning syngeneic, humanized, genetically engineered, orthotopic, and cell-line–derived xenograft mouse models—to support rigorous evaluations of therapeutic efficacy and underlying mechanisms.